- Attorney Docket No.: 6116.200-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application Commissioner for Patents Washington, DC 20231

Express Mail Label No. <u>EL636736748US</u> Date of Deposit January 10, 2001

Sir:

This is a request for filing an application under 37 C.F.R. 1.53(b) of

Applicant(s): Keith Anderson et al.

Title: Transepithelial Delivery Of GLP-1 Derivatives

30 pages of specification 0 sheets of Formal Drawings

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee: \$710.00

Total Claims: $13 - 20 = 0 \times 18 =$ \$0


Independent Claims: $5 - 3 = 2 \times 80 = 160.00

Total Fee: \$870.00

Priority of Danish application no. 2000 00030 filed on January 11, 2000 is claimed under 35 U.S.C. 119. A certified copy is submitted herewith.

Priority of U.S. provisional application no. 60/177,002 filed on January 19, 2000 is claimed under 35 U.S.C. 119.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.



Respectfully submitted,

Date: January 10, 2001

Valeta U. Gregg, Reg. No. 35,127 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

(212) 867-0123



Attorney Docket No.: 6116.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application Commissioner for Patents Washington, DC 20231

Re: U.S. Patent Application for

Title: Transepithelial Delivery Of GLP-1 Derivatives

Applicants: Keith Anderson et al.

Sir:

Express Mail Label No. EL636736748US

Date of Deposit: January 10, 2001

I hereby certify that the following attached paper(s) or fee

- 1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
- 2. Patent Application
- 3. Unexecuted Combined Declaration and Power of Attorney
- 4. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Sylvia @pnzalez

(Name of person majling paper(s) or fee

(Signature of person mailing paper(s) or fee)

Mailing Address: Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10017 (212)867-0123 10825 U.S. PTO 09/757788